Announcement of prospectus regarding rights issue in Active Biotech AB (publ)
The Swedish language prospectus regarding the rights issue in Active Biotech AB (publ) is now available at the company's website, www.activebiotech.com, and at the company's office, address Scheelevägen 22, SE-220 07, Lund, Sweden. The prospectus may also be obtained from the company via telephone, +46-46 19 20 00. Documents incorporated by reference in the prospectus are also available in accordance with the above.
The prospectus including issue documentation will be distributed to shareholders and representatives of shareholders, whose names are entered in the share register kept by Euroclear Sweden AB on the record date 20 May 2009.
The English language prospectus will be published within the next few days.
Lund, May 18, 2009
Active Biotech AB (publ)
For further information, please contact:
Tomas Leanderson, President & CEO
Tel: +46-46 19 20 95
Hans Kolam, CFO
Tel: +46-46 19 20 44
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on May 18, 2009.
Active Biotech AB (org. no. 556223-9227)
P.O. Box 724, SE-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46-19 11 00
This press release does not constitute an offer of any securities of Active Biotech. The rights issue is not directed to shareholders or other investors domiciled in the United States, Canada, Japan or Australia, or in any other country where participation in the issue would require additional prospectuses, registration or other measures other than those pursuant to Swedish law or would conflict with regulations in such country. No shares, interim shares, subscription rights or other securities issued by Active Biotech have been or will be registered in accordance with the United States Securities Act of 1933, or in accordance with any securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, interim shares, subscription rights or other securities issued by Active Biotech may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration.